Assuntos
Síndromes Mielodisplásicas , Idoso , Transplante de Medula Óssea , Causas de Morte , Protocolos Clínicos/normas , Citarabina/administração & dosagem , Citarabina/farmacologia , Citarabina/uso terapêutico , Árvores de Decisões , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Humanos , Síndromes Mielodisplásicas/diagnóstico , Síndromes Mielodisplásicas/epidemiologia , Síndromes Mielodisplásicas/terapia , Prognóstico , Taxa de SobrevidaRESUMO
The Nutrition Screening Initiative suggests an adaptable, tiered approach to screening for poor nutritional status in older Americans. The first level of screening is a checklist to be completed by elderly individuals or their caregivers. This checklist, which will be widely disseminated, describes the warning signs of poor nutritional status. It is anticipated that individuals will approach their physicians on the basis of scores on this checklist. Also included are two screening tests designed to help clinicians more easily detect poor nutritional status, or risk factors for poor nutrition, in their patients. The level I screen is to be completed by a social service or health care professional, or by other trained personnel. The level II screen focuses on additional information to be obtained following referral to a physician or other qualified health care professional.
Assuntos
Avaliação Geriátrica , Indicadores Básicos de Saúde , Avaliação Nutricional , Idoso , Algoritmos , Controle de Formulários e Registros , Humanos , Métodos , Inquéritos e QuestionáriosRESUMO
Treating long-term bone marrow culture with 10(-7)-10(-5) M methotrexate caused a 95% reduction in myelopoiesis as assessed by supernatant cell count and granulocyte/macrophage colony forming unit number. The suppression was irreversible with 10(-5) M methotrexate. Complete recovery of myeloid cell production occurred four and five weeks after cultures were treated with either 10(-7) M or 10(-6) M methotrexate, respectively. The suppression of myelopoiesis was completely prevented if 10(-3) M leucovorin was added to culture within 6 h of 10(-6) M methotrexate. The addition to culture of lung conditioned medium containing high concentrations of granulocyte/macrophage colony-stimulating factor shortened the time of myelopoietic suppression by one week. The addition of WEHI-3B medium containing both interleukin 3 and GM-CSF shortened the suppression by two weeks. This in vitro model provides unique opportunities to examine mechanisms involved in the myelopoietic and chemotherapy-induced suppression. A close analysis of approaches to modify the recovery process will also be possible.